Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer's disease

Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease.

MAIN RESULTS At 60 weeks, there were no significant differences between donepezil and placebo in institutionalisation rates or progression to disability in people with mild to moderate Alzheimer’s disease (see http:// www.ebmentalhealth.com/supplemental for table). There were no significant differences in institutionalisation rates between the 10 mg and 5 mg donepezil groups (10 mg v 5 mg: 37 v...

Preventing Long Term Institutionalisation

It is also necessary to restructure and modernise available community support services for families with children. Efforts are under way to upgrade home visiting nursing services for families with newborn infants. Low cost or free child care for working mothers using the creche system is an option thought to have practical merit, although the costs ofexpanding cr&che care would be high. Regular...

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

BACKGROUND Cholinesterase inhibitors produce small improvements in cognitive and global assessments in Alzheimer's disease. We aimed to determine whether donepezil produces worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers' psychological wellbeing, or delay in institutionalisation. If so, which patients benefit, from what dose, and for how long? ...

Are there long-term benefits of donepezil in Alzheimer's disease?

Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer's disease in the long term.

MAIN RESULTS Compared with placebo, neither vitamin E nor donepezil altered the probability of progression to Alzheimer’s disease after three years (vitamin E v placebo: HR for progression 1.02, 95% CI 0.74 to 1.41; donepezil v placebo: HR for progression 0.80, 95% CI 0.57 to 1.13). However, there was some indication that donepezil slowed progression to Alzheimer’s disease over the first two ye...